CJC-1295 with DAC (5mg)

What is CJC-1295 w/DAC?

CJC-1295 with DAC is a modified growth-hormone-releasing hormone (GHRH) analog. DAC means Drug Affinity Complex. This catalog lists a 5mg vial for in-vitro laboratory research, not a finished medicine.

Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

CJC-1295 with DAC and Mod GRF 1-29, often called CJC-1295 No DAC, are distinct constructs. Verify the sequence, DAC modification and molecular identity against an original matching lot document. A catalog name or CAS number alone is not confirmation.

What mechanisms are being studied?

GHRH signals the pituitary to release growth hormone. The DAC modification allows the studied molecule to bind albumin, a blood protein. Researchers examine how this changes the duration of growth hormone and insulin-like growth factor I (IGF-I) responses.

What are the research questions?

• Albumin binding and persistence of a defined GHRH analog
• Growth hormone and IGF-I responses in controlled experimental settings
• Whether hormone pulses persist during prolonged GHRH stimulation

What does the published work describe?

Jetté and colleagues' 2005 paper characterized CJC-1295 as a long-lasting GRF analog. Teichman and colleagues' 2006 trials in healthy adults measured prolonged growth hormone and IGF-I responses. Ionescu and Frohman's 2006 study examined continued pulsatile growth hormone secretion. These papers describe the tested DAC-containing material, not a clinical trial of this catalog vial.

Experimental models in the cited papers

• Experimental characterization of a long-lasting GRF analog
• Healthy adults: growth hormone and IGF-I measurements
• Human growth hormone pulsatility study

What could future research explore?

Future research could investigate how albumin binding changes receptor signaling and hormone feedback. Possible therapeutic applications would require condition-specific trials with a defined formulation. Changes in hormone measurements alone do not establish improvements in recovery, sleep or body composition.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

The cited studies do not establish this research vial's identity, purity, effectiveness or safety. Findings for CJC-1295 with DAC cannot be transferred to Mod GRF 1-29 without DAC or to a peptide blend. Short studies in healthy adults do not establish long-term safety or treatment benefit.

Study references

1. Jetté L, et al. Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID 15817669
2. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID 16352683
3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. PMID 17018654

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.